MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma

Leukemia

Volumn 27, Issue 6, 2013, Pages 1381-1390

  Wenzel, S S ^a   Grau, M ^b   Mavis, C ^c   Hailfinger, S ^d   Wolf, A ^a   Madle, H ^a   Deeb, G ^c   Dorken B ^a   Thome, M ^d   Lenz, P ^b   Dirnhofer, S ^e   Hernandez Ilizaliturri, F J ^c   Tzankov, A ^e   Lenz, G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

aCGH; apoptosis; diffuse large B cell lymphoma; MCL1; therapy resistance

Indexed keywords

OBATOCLAX; PROTEIN MCL 1; STAT3 PROTEIN;

ARTICLE; CANCER RESISTANCE; CELL DEATH; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; GERMINAL CENTER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84878907241     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.367     Document Type: Article

References (44)

1. Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011; 29: 1803-1811.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
4. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996. (Pubitemid 37087056)
5. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862. (Pubitemid 37152922)
6. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879. (Pubitemid 37486965)
7. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861. (Pubitemid 40731764)
8. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430. (Pubitemid 43855045)
9. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
10. Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010; 91: 456-463.
11. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
12. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
13. Mandelin 2nd AM, Pope RM. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 2007; 11: 363-373. (Pubitemid 46290959)
14. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326. (Pubitemid 28406819)
15. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
16. Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005; 4: 267-276. (Pubitemid 41351285)
17. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2010; 30: 1963-1968.
18. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006; 44: 151-157. (Pubitemid 41772529)
19. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000. (Pubitemid 28078303)
20. Ji M, Li J, Yu H, Ma D, Ye J, Sun X et al. Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. Br J Haematol 2009; 145: 648-656.
21. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194-199. (Pubitemid 35177447)
22. Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001; 97: 3902-3909.
23. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-110.
24. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130. (Pubitemid 47199123)
25. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
26. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520-13525.
27. Nagel S, Hirschmann P, Dirnhofer S, Gunthert U, Tzankov A. Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 2010; 38: 38-45.
28. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207.
29. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003; 199: 90-97. (Pubitemid 36054733)
30. Michels J, Foria V, Mead B, Jackson G, Mullee M, Johnson PW et al. Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 2006; 132: 743-746. (Pubitemid 43381636)
31. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009; 22: 476-487.
32. Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, Charton JE et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. PNAS 2011; 108: 14596-14601.
33. Mehra S, Messner H, Minden M, Chaganti RS. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 2002; 33: 225-234. (Pubitemid 34130928)
34. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701-3713.
35. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515-1523. (Pubitemid 351213441)
36. Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y et al. 6-Bromoindirubin-3'- oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 2011; 71: 3972-3979.
37. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-19517.
38. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.
39. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20: 7342-7351. (Pubitemid 33078205)
40. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183-3190. (Pubitemid 41565917)
41. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A et al. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004; 35: 1095-1100. (Pubitemid 39165341)
42. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
43. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92: 234-240. (Pubitemid 28303198)
44. Green MR, Aya-Bonilla C, Gandhi MK, Lea RA, Wellwood J, Wood P et al. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 2011; 50: 313-326.